Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025

Published on 30 Jan 2025 on Zacks · via Yahoo Finance

The company’s sales and earnings growth outlook for 2025 seems quite optimistic, with expectations...

Read the rest of the article

Start tracking your investments with Statfolio

CRSP beat on earnings in three of the trailing four quarters and missed the mark in the other,...

Zacks · via Yahoo Finance 3 Feb 2025

Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of boom...

Pharmaceutical Technology · via Yahoo Finance 3 Feb 2025

L'Oreal sells its €3 billion stake in Sanofi

Investing.com 3 Feb 2025

(Bloomberg) -- Cosmetics giant L’Oreal SA is selling a €3 billion ($3.1 billion) stake in Sanofi...

Bloomberg · via Yahoo Finance 3 Feb 2025

The company’s sales and earnings growth outlook for 2025 seems quite optimistic, with expectation...

Zacks · via Yahoo Finance 30 Jan 2025

Sanofi (EPA:SASY) (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.2...

Investing.com 30 Jan 2025

(Bloomberg) -- Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits...

Bloomberg · via Yahoo Finance 30 Jan 2025

The Sarclisa combination therapy was approved for a similar indication by the FDA in September, a...

Zacks · via Yahoo Finance 23 Jan 2025

Sanofi (SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly...

Seeking Alpha 22 Jan 2025

The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA’s SNY Genzyme Co...

Benzinga 22 Jan 2025